Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Algernon Pharmaceuticals (AGN) has included novel salt forms of DMT in its intellectual property patent applications for AP-188
  • Different salts can improve the core drug in several ways, including improved efficacy, safety/tolerability, and stability
  • The company believes that it has maximized its intellectual property position around DMT
  • N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug
  • Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications
  • Algernon Pharmaceuticals Inc. (AGN) opened trading at C$9.00 per share

Algernon Pharmaceuticals (AGN) has included novel salt forms of DMT in its intellectual property patent applications for AP-188 (“N,N-dimethyltryptamine” or “DMT”).

A novel salt form of a drug is a new and separate structure from the original compound and is considered a new composition of matter.

CEO Chris Moreau sat down with Dave Jackson to discuss the news.

Many drug compounds’ core structures can be paired with a salt. Different salts can improve the core drug in several ways, including improved efficacy, safety/tolerability, and stability.

The company believes that it has maximized its intellectual property position around DMT, which includes filing patent applications for new novel salt forms, as well as dosing, formulation, and method of use patent applications for stroke rehabilitation.

Algernon recently announced that it has filed a combined Clinical Trials of Investigational Medicinal Products and Ethics Approval application, with the United Kingdom Medicines and Healthcare Products Regulatory Agency for its planned Phase 1 DMT clinical human stroke study.

N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug-producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin.

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications.

Algernon Pharmaceuticals Inc. (AGN) opened trading at C$9.00 per share.

More From The Market Herald

" Top 5 Stories of the Week: Empower Clinics (CSE:CBDT), Eat Well Group (CSE:EWG), Tocvan Ventures (CSE:TOC), Mullen Group (TSX:MTL), EasTower Wireless (TSXV:ESTW)

With inflation reaching 7.7 per cent in May, the highest in 40 years, recessionary fears are running rampant.

" @ the Bell: Summer blues for TSX, Wall Street sees worst half since 1970

On the last day before the Canada Day long weekend, the TSX finished lower by triple digits in broad-based decline as commodity prices

" Top 5 Stories of the Week: Baselode Energy Corp. (TSXV:FIND), Green River Gold (CSE:CCR), Mantaro Precious Metals (TSXV:MNTR), Granite Creek Copper (TSXV:GCX), Tocvan Ventures (CSE:TOC)

As the first half of 2022 draws to an end, the news about inflation and the stock market performance has not given investors

" This Company is Discovering More Gold in Ecuador, with its Copper Story Just Starting

While gold production in countries such as Peru, — which is South America’s leading gold producer — Brazil, Colombia, Bolivia and Argentina dominate